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Introduction: A higher prevalence of metabolic syndrome (MetS) has been described in rheumatoid arthritis (RA),
along with an association with disease activity. Objectives were to describe prevalence of MetS at RA diagnosis in a
cohort of Mexican Mestizo early RA patients, and to define a causal association between MetS and disease activity.
Methods: The study population was a prospective cohort. At baseline and at fixed 6-months-intervals, patients had
medical evaluations, fasting serum glucose, triglycerides, high-density lipoprotein cholesterol and acute reactant-phase
determinations. MetS was defined according to international criteria and body mass index (BMI) ≥30 kg/m2 was used
as a surrogate of the waist circumference. The study was approved by the internal review board. Appropriated statistics
and Cox regression analysis were used. All statistical tests were two-sided and evaluated at the 0.05 significance level.
Results: Up to March 2014, data from 160 patients were analyzed. At baseline, they were more frequently middle-aged
females and had moderate to high disease activity. Prevalence of MetS varied from 11.3% to 17.5% in patients and was
lower to that from matched controls (versus 26.3% to 30%, P ≤0.01).
Up to last follow-up, 39 patients (34.5%) developed incidental MetS. In the Cox regression analysis, cumulative disease
activity score (DAS) 28 (odds ratio (OR): 1.81, 95% confidence interval (CI): 1.346 to 2.433, P = 0.000) and baseline BMI
(OR: 1.13, 96% CI: 1.035 to 1.236, P = 0.007) were the only predictors for incidental MetS.
RA patients with incidental MetS accumulated more disease activity and had less frequent remission than their
counterparts. Logistic regression analysis showed that incidental MetS (OR: 0.2, 95% CI: 0.01 to 0.99, P = 0.052) and
baseline DAS28 (OR: 0.4, 95% CI: 0.2 to 0.9, P = 0.02) were the only predictors for achieving or maintaining sustained
(≥6 months) remission.
Conclusions: MetS prevalence in a cohort of early RA patients was lower than that from matched controls. Cumulative
disease activity and higher BMI were risk factors for incidental Mets; higher baseline disease activity and incidental MetS
prevented sustained remission. In addition to disease activity, MetS needs to be controlled to impact disease outcomes.* Correspondence: virtichu@gmail.com
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Cardiovascular (CV) disease is the leading cause of death
in patients suffering from rheumatoid arthritis (RA)
[1-3]. Factors that contribute to increased CV risk are
genetic factors, chronic inflammation, traditional CV
risk factors along with disease and treatment-related fac-
tors [4-11]. More recently, it has been proposed that
metabolic syndrome (MetS) should be added to the list;
in the general population, MetS identifies patients at risk
of developing coronary heart disease later in life, with a
relative risk of 2.7 [12].
MetS refers to a clustering of specific classical CV risk
factors, the combination of which is thought to be associ-
ated with increased CV risk beyond the sum of the indi-
vidual components [13]. The existing literature suggests
that inflammatory processes are involved in MetS patho-
genesis. Regarding prevalence of MetS in RA, there have
been conflicting results but the most recent meta-analysis
of 12 observational, cross-sectional studies involving 2,283
Caucasian and Asian RA patients showed a significantly
increased prevalence when compared with 4,403 controls
[14]. Chung and colleagues found that the frequency of
MetS was greater in patients with long-term disease (42%)
than in patients with early arthritis (30%) [15]; Dao and
colleagues confirmed the association between RA and
MetS in 105 Vietnamese women with short disease dur-
ation and additionally showed that individual components
of the MetS, such as hypertension, high-density lipopro-
tein cholesterol levels and abdominal obesity, were more
frequent in RA patients than in their matched controls
[16]. Additional studies have found association with some
components of the MetS and disease activity [17-19], al-
though the cross-sectional design of the studies prevents
identification of causal associations.
In México, data from the National Health and Nutrition
Survey 2006 have shown a high prevalence of MetS among
adults, ranging from 36.8 to 49.8% depending on the cri-
teria applied. Notably, MetS was more prevalent among
women, among the less educated individuals and among
those with lower incomes [20]. Hispanic population-based
studies have also shown an increased susceptibility in
Mexican adults and confirmed local data [21].
A goal of clinical management in individuals with MetS
is to reduce the risk of clinical atherosclerotic disease (and
related comorbid conditions), which is a major cause of
death in patients with RA [22]. Accordingly, RA patients
with such comorbidity need to be identified. Furthermore,
the relationship between disease activity and MetS needs
to be clarified in order to understand how achievement of
major outcomes as sustained remission may further im-
pact on CV mortality. In the literature there is a paucity of
data in Latin American countries where both entities,
MetS and RA, have distinctive epidemiological, serological
and clinical characteristics [23].The main objectives of the study were: first, to describe
the prevalence and characteristics of MetS at RA diagnosis
in a cohort of Mexican Mestizo early RA patients and
compare these with data from healthy matched controls;
and second, to define the relationship between MetS and
disease activity. Based on our cohort’s characteristics (high
disease activity at enrollment, high remission rate after
treat-to-target strategy and substantial follow-up [24]),
two secondary objectives were established: to investigate
MetS as a risk factor to achieve a first sustained remission
status; and to determine whether incidental MetS over
follow-up impacts disease activity-related outcomes.
Methods
Setting and study population
The Early Arthritis Clinic of the Instituto Nacional de
Ciencias Médicas y Nutrición Salvador Zubirán was
established in February 2004. Patients referred to the
clinic had suspicion of RA and symptom duration of less
than 12 months. Patients with confirmed recent-onset
RA also attend the clinic; in such patients, the time from
diagnosis to first evaluation is ≤5 weeks.
Patients received treat-to-target-oriented treatment.
Traditional disease-modifying anti-rheumatic drugs
(DMARDs) were used in 99% of our population, with
or without corticosteroids (20 to 40%).
Clinical evaluations
At baseline, a complete medical history and sociodemo-
graphic characteristics were obtained. Blood samples
after 9 to 12 hours fast included at least serum glucose
(GLU), total cholesterol, triglycerides (TG), high-density
lipoprotein-cholesterol (C-HDL), low-density lipoprotein-
cholesterol, uric acid, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), rheumatoid factor and
antibodies to cyclic citrullinated proteins (ACCP). Urine
analysis was also performed. For serum GLU and lipid
determinations, commercially available reagents from
Beckman Co. (Limerick, Ireland) for the Synchron
analyzer (Laboratorios Clínicos del Instituto Nacional de
Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
City, Distrito Federal, México) were used. The laboratory
obtained ISO 9001:2008 certification (since 30 April 2004,
valid from 29 April 2013 until 28 April 2016).
Standard baseline and consecutive rheumatic evaluations
included, height, weight and blood pressure measurements,
extended joint counts, physician and patient-reported out-
comes [25,26], disease activity score evaluated in 28 joints
(DAS28) [27], adverse events and comorbidity. Blood pres-
sure was measured twice in each case in which initial
measurement was ≥130/90 mmHg unless the patient had a
previous diagnosis of systemic arterial hypertension. Mea-
surements were performed after a 5-minute resting period.
Body weight and height were performed by a trained nurse,
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brated according to the manufacturer’s recommendations.
Patients were evaluated every 2 months during the first
2 years of follow-up, and thereafter every 2, 4 or 6 months
(fixed and scheduled for all patients). At fixed 6-month in-
tervals, analysis in order to measure serum GLU, total chol-
esterol, TG, C-HDL, low-density lipoprotein-cholesterol,
uric acid, ESR, CRP and urine analysis were scheduled.
Medical evaluations were performed by the same rheuma-
tologist and the information was recorded on standardized
formats.
RA treatment records included previous treatment
(defined as prescribed during the month prior to the base-
line evaluation) and current treatment (at baseline and
consecutive evaluations), which included names, doses,
schedule, order start and stop dates of DMARDs, of corti-
costeroids and of nonsteroid anti-inflammatory drugs. In
addition, any other drug indicated for a comorbid condi-
tion was also recorded; for the present study, names,
doses, schedule, order start and stop dates of antihyper-
tensive, antidiabetic and lipid-lowering medications were
obtained. Information regarding treatment was recorded
after a direct interview on a drug record registry applied at
scheduled evaluations [28].
Up to March 2014, charts from 162 consecutive pa-
tients with early RA were reviewed. In order to accom-
plish the first objective, only RA patients with completed
baseline blood pressure, weight and height, and serum
TG, C-HDL and GLU levels were included (two patients
were excluded); there were 160 patients left.
Of the 160 patients with complete baseline data, 19
were lost to follow-up soon after the baseline evaluation
(and their baseline characteristics did not differ from
those patients with follow-up) and 28 additional patients
had prevalent MetS. Accordingly, there were 113 pa-
tients with at least 6 months of follow-up and MetS-free
baseline, in whom incidental MetS was investigated.
Finally, to accomplish the second objective related to
MetS and its impact on remission, data from patients
with at least 24 months of follow-up were analyzed
(n = 133). This lag time was chosen based on previous
reports that defined median time to sustained remission
in our cohort as 13.6 (±8.8) months [29].
Control population
To achieve the first objective, one control for each RA pa-
tient was randomly selected from a local database that
included data from more than 10,000 Mexican Mestizo
adults without either known medical condition or treat-
ment, in whom serum samples were obtained in order to
investigate the prevalence of the MetS in Central Mexico.
Controls were matched according to age (±5 years), gen-
der, smoking habit (see definition below), years of educa-
tion, menopause status and urban residency.To achieve the second objective, a case–control study
nested within a cohort was designed; cases consisted of
RA patients with incidental MetS and controls consisted of
RA patients who never developed MetS during their
follow-up. Controls were matched according to gender,
age, index date (as defined when MetS was diagnosed or
equivalent visit in MetS-free RA patients), menopause sta-
tus, presence of rheumatoid factor or ACCP, and follow-up.
Variables and definitions
Body mass index (BMI) was calculated as weight (kg)/
height (m2).
Smoking status was self-reported at the baseline evalu-
ation and categorized as never smoker, former smoker (at
least one cigarette per day for at least 3 months during
their lifetime but who do not currently smoke) or current
smoker (at least one cigarette/day for at least 3 months).
Postmenopausal women were self-reported and defined as
women ≥48 years of age who have been amenorrheic for at
least 2 years, or females with bilateral oophorectomy or
females with documented hysterectomy aged ≥47 years [30].
Fasting GLU, uric acid, total cholesterol, low-density
lipoprotein-cholesterol, C-HDL and TG were measured
in serum and reported in milligrams per deciliter.
Sustained remission was defined based on the DAS28 if
score ≤2.6 [31] and according to 2012 American College
of Rheumatology/European League Against Rheumatism
criteria [32] and if maintained for at least 6 months of
follow-up.
Hypertension was defined if recorded on the charts, or
antihypertensive medication was used, or a diastolic
blood pressure ≥90 mmHg was detected or a systolic
blood pressure ≥140 mmHg was detected.
Diabetes mellitus was defined if a physician diagnosis was
recorded on the charts, if antidiabetic medication was re-
corded or if a fasting blood sugar level ≥126 mg/dl was
detected.
MetS was defined according to three sets of criteria
(Table 1) [22,33,34]. In all of these sets, BMI ≥30 kg/m2
was considered a surrogate of waist circumference ≥102 cm
in males and ≥88 cm in females.
Ethics
The study was approved by the Ethics Committee of the
Instituto Nacional de Ciencias Médicas y Nutrición.
Written informed consent was obtained in order to have
the patient’s charts reviewed and data presented in sci-
entific forums or published.
Statistical analysis
Distribution of each variable was analyzed. Student’s t
test and the chi-square test were used for normally dis-
tributed variables and the Mann–Whitney U test for
non-normally distributed variables.
Table 1 Metabolic syndrome sets of criteria
2001 NCEP ATP III definition AHA/NHLBI definition IDF definition
(any three of five) (any three of five) (requireda and any two of four criteria left)
BMI ≥30 kg/m2 BMI ≥ 30 kg/m2 BMI ≥30 kg/m2 a
TG ≥150 mg/dl TG ≥150 mg/dl or treatment for elevated TG TG ≥150 mg/dl or treatment for elevated TG
C-HDL <40 mg/dl in men C-HDL <40 mg/dl in men C-HDL <40 mg/dl in men
C-HDL <50 mg/dl in women C-HDL <50 mg/dl in women C-HDL <50 mg/dl in women
Blood pressure ≥130/85 mmHg or previous
hypertension diagnosis
Blood pressure ≥130/85 mmHg or previous
hypertension diagnosis
Blood pressure ≥130/85 mmHg or previous
hypertension diagnosis
Fasting glucose ≥110 mg/dl or previous type 2 DM Fasting glucose ≥100 mg/dl or previous type 2 DM Fasting glucose ≥100 mg/dl or previous type 2 DM
Criteria according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) definition [33], the American Heart Association/National
Heart, Lung and Blood Institute (AHA/NHLBI) definition [22] and the International Diabetes Federation (IDF) definition [34]. BMI, body mass index; C-HDL, high-
density lipoprotein-cholesterol; DM, diabetes mellitus; TG, triglycerides. aIs a prerequisite risk factor for the MetS diagnosis.
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disability) or variables (CRP, ESR), the mean of consecu-
tive values from corresponding evaluations was obtained.
Follow-up missing data varied from 3% (for BMI) to
20% (for serum GLU levels). Imputation was calculated
for linear regression method, considering an arbitrary
pattern of missing values.
Prevalence of MetS was determined based on different
sets of criteria applied at baseline or within 2 months
from baseline evaluation. The prevalence of the MetS
was compared between early RA and matched controls
using Fisher’s exact test.
Logistic and Cox regression’s models were used: to
evaluate the risk of MetS (defined at the baseline evalu-
ation); to achieve remission; to identify predictors of inci-
dental MetS; and to investigate incidental MetS as a
predictor of sustained remission. In all cases, selection of
variables to be included was based on their statistical sig-
nificance in the bivariate analysis; a cutoff point was estab-
lished based on the number of variables a priori included
in order to avoid overfitting of the models; based on the
number of outcomes of interest, four or five variables were
included. Correlation between variables was also exam-
ined, and when significant only one variable was selected.
Selection was based on variables’ clinical relevance; in all
cases, correlated variables were switched into the models
to test the integrity of the results. Finally, if a variable was
deemed to be clinical significant, its inclusion was forced
into the model (cumulative treatment).
In the first model, there were no variables with statis-
tical significance in the univariate analysis and the covar-
iates included a priori were age, gender and MetS at
baseline evaluation.
In the second analysis, variables selected were age (corre-
lated to menopause, r = 0.5 and to years of formal educa-
tion, r = 0.3), BMI, cumulative DAS28 (correlated to
cumulative ESR, r = 0.75, to cumulative CRP, r = 0.4 and to
cumulative HAQ, r= 0.67) and follow-up (correlated to ero-
sions at index date, r = 0.26), P ≤0.001 for all correlations.In the third analysis, variables included were baseline
DAS28 (correlated to ESR, r = 0.6, to HAQ, r = 0.67 and
to CRP, r = 0.6), incidental MetS (correlated to BMI, r =
0.4 and to obesity, r = 0.3), disease duration at baseline,
ACCP and age (P ≤0.001 for correlations); cumulative
treatment was also forced into models.
All statistical tests were two-sided and evaluated at the
0.05 significance level. Statistical analysis was performed
using the SPSS/PC program (v.17.0; IBM SPSS Statistics,
Chicago, IL, USA).
Results
Population characteristics at cohort entry
At baseline 160 patients had complete data, as summa-
rized in Table 2. Patients were more frequently middle-
aged females (142 female, mean ± standard deviation
age: 38.1 ± 12.8 years) and had median (range) BMI of
25.9 kg/m2 (18.1 to 46.8 kg/m2). The population had
short disease duration, was most frequently rheumatoid
factor-positive and ACCP-positive, and had high disease
activity and moderate disability. A minority of patients
had erosive disease (9.4%). Comorbid conditions were
present in 82 patients (51.3%), among which were obes-
ity in 35 patients (21.9%), hypertension in 13 patients
(8.1%) and diabetes in six patients (3.8%). Few patients
were receiving DMARDs when referred to the clinic
(27.5%), although 36.9% were on oral corticosteroids.
Characteristics and prevalence of metabolic syndrome in
RA patients and comparison with matched healthy
controls (first objective)
In RA patients, the prevalence of MetS varied from
11.3% (according to the International Diabetes Feder-
ation definition) to 17.5% (according to the American
Heart Association/National Heart, Lung and Blood Insti-
tute (AHA/NHLBI) definition). In healthy matched con-
trols, prevalence of Mets was significantly higher and
varied from 26.3% (according to the International Dia-
betes Federation definition) to 30% (according to the
Table 2 Baseline characteristics of the whole population and comparison between patients with/without metabolic
syndrome (according to AHA/NHLBI definition)
Characteristic Controls Whole population Patients with MetS Patients without MetS P valuea
(n = 160) (n = 160) (n = 28) (n = 132)
Socio-demographic
Female gender 142 (88.8) 142 (88.8) 22 (78.6) 120 (90.9) 0.09
Age (years) 38 ± 12.4 38.1 ± 12.8 43.1 ± 10.5 37 ± 13 0.02
Years of formal education 10.9 ± 3.8 10.9 ± 3.8 10.8 ± 3.5 11 ± 3.8 0.87
Current smokers 16 (10) 16 (10) 2 (7.1) 14 (10.6) 0.74
Females with menopause (142 female) 14 (9.9) 14 (9.9) 3 (13.6) 11 (9.2) 0.46
BMI (kg/m2) 25.5 (19.2 to 41) 25.9 (18.1 to 46.8) 30.2 (23 to 46.8) 24.8 (18 to 41.7) 0.000
Disease characteristics
Disease duration (months) NA 5.3 (0.47 to 11.5) 4.3 (1.4 to 10.5) 5.3 (0.5 to 12.5) 0.13
Patients with RF NA 130 (81.3) 25 (89.3) 105 (79.5) 0.29
Patients with ACCP NA 134 (83.8) 26 (92.9) 108 (81.8) 0.26
DAS28 NA 6 (2 to 8.7) 6.1 (3 to 8.6) 6 (2 to 8.7) 0.94
ESR (mm/hour) NA 23 (2 to 102) 22 (3 to 77) 23 (2 to 102) 0.86
CRP (mg/dl) NA 0.73 (0 to 14.7) 0.76 (0.1 to 8.5) 0.73 (0 to 14.7) 0.95
HAQ NA 1.4 (0 to 3) 1.4 (0 to 3) 1.5 (0.3) 0.39
Patients with erosions NA 15 (9.4) 6 (21.4) 9 (6.8) 0.03
Comorbid conditions
Patients with ≥1 comorbid condition NA 82 (51.3) 22 (78.6) 60 (45.5) 0.001
Patients with diabetes NA 6 (3.8) 5 (17.9) 1 (0.8) 0.001
Patients with hypertension NA 13 (8.1) 9 (32.1) 4 (3) 0.000
Patients with BMI ≥30 kg/m2 NA 35 (21.9) 18 (75) 17 (12.5) 0.000
Treatment
Patients with DMARDs NA 44 (27.5) 9 (32.1) 35 (26.5) 0.64
Patients with corticosteroids NA 59 (36.9) 11 (39.3) 48 (36.4) 0.83
Patients with antimalarials NA 26 (16.3) 5 (17.9) 21 (15.9) 0.78
Patients with other drugs NA 83 (51.9) 14 (50) 69 (52.3) 0.84
Data presented as n (%), mean ± standard deviation or median (range). ACCP, antibodies to cyclic citrullinated peptides; AHA/NHLBI, American Heart Association/
National Heart, Lung and Blood Institute; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD, disease-
modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; NA, not applicable;
RF, rheumatoid factor. aComparison between rheumatoid arthritis patients with/without MetS.
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for all comparisons).
Distribution of individual components of the MetS in
RA patients and controls was as follows: BMI ≥30 kg/m2
ranged from 64.3 to 100%, TG ≥150 mg/dl from 92.9 to
95.8%, C-HDL <40 mg/dl (men) or <50 mg/dl (women)
from 94.4 to 96.4%, blood pressure ≥130/85 mmHg (or
previous hypertension diagnosis) from 20.8 to 22.2%,
and fasting GLU ≥100 mg/dl (or previous type 2 diabetes
mellitus) from 27.8 to 53.6%. Comparison of individual
components between RA patients and healthy controls
showed that the former less frequently had the BMI
component and tend to more frequently have the GLU
component, as shown in Table 3.
Comparison of baseline characteristics between pa-
tients with/without prevalent MetS is summarized inTable 2. Patients with MetS according to AHA/NHLBI
definition were older, had greater BMI, had more erosive
disease and tended to be more frequently men than their
counterparts. As expected, patients with MetS had also
more diabetes, hypertension and obesity, while other co-
morbid conditions were equally represented. Variables re-
lated to disease activity and treatment were similar in both
groups. Similar results were obtained when the 2001
National Cholesterol Education Program Adult Treatment
Panel III definition and the International Diabetes Feder-
ation definition were applied (data not shown).
Metabolic syndrome and the probability for achieving
remission status (second objective)
As already mentioned, 133 patients had at least 24 months
of follow-up, of whom 108 (81%) had at least ≥1 sustained
Figure 1 Comparison of prevalence of metabolic syndrome
between rheumatoid arthritis patients and matched controls.
Numbers inside bars represent the number of patients and controls
with metabolic syndrome according to the three different
definitions. AHA/NHLBI, American Heart Association/National Heart,
Lung and Blood Institute; IDF, International Diabetes Federation;
NCEPT/ATPIII, National Cholesterol Education Program Adult
Treatment Panel III; RA, rheumatoid arthritis.
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Against Rheumatism remission state. They achieved re-
mission at (median, range) 14 months (4 to 80 months) of
follow-up and remained in remission for 16 months
(6 to 104 months). Twenty-two out the 108 patients who
achieved remission (20.4%) had MetS according to AHA/
NHLBI criteria and no differences were seen in the per-
centage of patients achieving remission, time to remission
state and time on sustained remission between patients
with/without MetS. Cox regression analysis did not iden-
tify MetS as a risk factor for any construct related to re-
mission (data not shown). Similar results were obtained
when remission was defined according to DAS28 (data
not shown).Table 3 Comparison of the distribution of individual
components of metabolic syndrome (according to AHA/







Patients who met AHA/NHLBI MetS
definition
28 (17.5) 48 (30) 0.01
Patients within each category of MetS
definition with a particular individual
component
BMI component 18 (64.3) 42 (87.5) 0.02
TG component 26 (92.9) 43 (89.6) 1
C-HDL component 27 (96.4) 46 (95.8) 1
Blood pressure component 10 (35.7) 11 (22.9) 0.29
Fasting glucose component 15 (53.6) 16 (33.3) 0.10
Data presented as n (%). AHA/NHLBI, The American Heart Association/National
Heart, Lung and Blood Institute; BMI, body mass index; C-HDL, high-density
lipoprotein-cholesterol; MetS, metabolic syndrome; RA, rheumatoid arthritis;
TG, triglycerides.Incidental metabolic syndrome in RA patients and
impacts on major outcomes (second objective)
To explore the relationship between MetS and disease
activity-related outcomes we first identified RA patients
who developed incidental MetS at some point during
their follow-up. According to the AHA/NHLBI defin-
ition, 39 patients (34.5%) out of 113 baseline MetS-free
patients with adequate follow-up developed incidental
MetS. The global MetS incidence rate was 8 per 100 per-
sons/year; as shown in Figure 2, the annual incidental
rate of MetS tended to decrease after the third year of
follow-up.
Baseline characteristics and cumulative disease charac-
teristics up to the index date (when incident MetS was
identified/or up to last follow-up) were then compared
between RA patients with/without incidental Mets. Re-
sults are summarized in Table 4 and showed that RA pa-
tients who developed incidental MetS were older, were
less educated, were more frequently postmenopausal,
had higher BMI, had more cumulative disease activity
and disability, had previous incidental MetS diagnosis,
developed erosive disease more frequently than their
counterparts and had longer follow-up. In order to iden-
tify predictors of MetS, different Cox regression models
were tested in which baseline demographic and an-
thropometric variables were included in addition to cu-
mulative variables related to disease activity. Table 5
presents the different models tested; in all of the models,
cumulative DAS28 and baseline BMI were the only pre-
dictors for incidental MetS. When RA-related treatment
was forced into the model, similar results were obtained.
We then explored the impact of MetS on disease activ-
ity. A case–control study nested within a cohort was de-
signed; among the 39 RA patients with incidental MetS,
30 were paired to 30 corresponding matched controls
(age, gender, index date, menopause status, RF, ACCP
and follow-up). Cumulative outcomes related to diseaseFigure 2 Annual metabolic syndrome incidence rate. MetS,
metabolic syndrome.
Table 4 Comparison of rheumatoid arthritis patient







(n = 74) (n = 39)
Socio-demographic
Female gender 68 (91.9) 35 (89.7) 0.74
Age (years) 33.6 ± 11.9 42.7 ± 13.8 0.000
Years of formal education 11.6 ± 3.6 10 ± 4.2 0.04
Current smokers 10 (13.5) 2 (5.1) 0.21
Females with menopause
(142 female)
4 (4.4) 7 (20) 0.03




5.4 (3.9 to 7) 5.3 (2.9 to 7.3) 0.38
Patients with RF 59 (79.7) 29 (74.4) 0.63
Patients with ACCP 63 (85.1) 29 (74.4) 0.21
Cumulativea DAS28 2.4 (2.1 to 3.05) 3.3 (2.7 to 5.8) 0.000
Cumulativea ESR
(mm/hour)
12.5 (8.6 to 18.2) 21 (10.2 to 35) 0.008
Cumulativea CRP (mg/dl) 0.28 (0.15 to 0.58) 0.52 (0.26 to 1.21) 0.007
Cumulativea HAQ 0.2 (0.12 to 0.43) 0.38 (0.25 to 1.13) 0.001
Patients with erosions at
index datea
27 (34.5) 23 (59) 0.03




35 (47.3) 20 (51.3) 0.67
Patients with diabetes 0 1 (2.6) 0.35
Patients with hypertension 1 (1.4) 3 (7.7) 0.12
Patients with
BMI ≥30 kg/m2
3 (4.1) 10 (25.6) 0.001
Treatment at baseline
Patients with DMARDs 15 (32.6) 15 (38.5) 0.12
Patients with
corticosteroids
26 (35.1) 12 (30.8) 0.68
Patients with
antimalarials
12 (16.2) 8 (20.5) 0.61
Patients with other drugs 37 (50) 22 (56.4) 0.56
Data presented as n (%), mean ± standard deviation or median (range). ACCP,
antibodies to cyclic citrullinated peptides; BMI, body mass index; CRP,
C-reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD,
disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate;
HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; RF,
rheumatoid factor. aConsidered up to MetS diagnosis in patients with incidental
MetS and up to last follow-up in the patients without incidental MetS.
Table 5 Cox regression models to define predictors for
incidental metabolic syndrome (according to AHA/NHLBI
definition)
Model 1 Model 2 Model 3
Age 1.005, 0.98 to 1.03 1.009, 0.98 to 1.04 0.99, 0.98 to 1.02
BMI 1.14, 1.04 to 1.26 1.14, 1.04 to 1.25
BMI ≥25 kg/m2 3.07, 1.7 to 9.26
Cumulative
DAS28
1.79, 1.33 to 2.43 1.92, 1.41 to 2.62 1.91, 1.37 to 2.68
Erosions at
index date
0.71, 0.32 to 1.6
Follow-up 0.99, 0.97 to 1.004 0.99, 0.98 to 1.01
Data presented as Exp (β), 95% confidence interval. AHA/NHLBI, American
Heart Association/National Heart, Lung and Blood Institute; BMI, body mass
index; DAS28, disease activity score evaluated in 28 joints.
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after the index date and results are summarized in
Figure 3A,B. RA patients with incidental MetS had
higher median (range) cumulative DAS28 after the index
date than RA patients who never developed MetS overfollow-up (Figure 3A); also, less RA patients from the
former group achieved or maintained remission while
more patients had disease flare or never achieved remis-
sion when compared with the control group (Figure 3B).
We then compared characteristics from patients who
achieved or maintain remission after the index date (n =
46) and those who never achieved remission (n = 14); as
shown in Table 6, the former had lower BMI, longer
disease duration at baseline evaluation, lower baseline
disease activity (as per DAS28, ESR and CRP) and dis-
ability, developed incidental MetS less frequently and
were more frequently obese at the baseline evaluation.
Baseline (not shown) and cumulative treatment before
sustained remission was similar (corticosteroid use and
number of DMARDs/patient). Finally, logistic regression
analysis was performed in order to identify predictors
for remission after incident MetS. Table 7 presents the
different models tested; in all of them, incidental MetS
and baseline DAS28 were the only predictors for achiev-
ing or maintaining a sustained remission status.
Discussion
In the present study we found that 11 to 18% of Mexican
Mestizo early RA patients had MetS diagnosed as a co-
morbid condition and this figure was lower for prevalence
of MetS in healthy controls. Distribution of the TG and C-
HDL components of MetS was similar between patients
and controls, but early RA patients presented less fre-
quently the BMI component while the controls showed a
similar tendency for the GLU and hypertension compo-
nents. Patients with prevalent MetS were older, had
greater BMI, had more radiographic damage and more
frequently had comorbid conditions related to MetS than
RA patients without the syndrome.
In 2008, Chung and colleagues were the first to demon-
strate that prevalence of MetS in patients with RA was
increased when compared with matched controls [15].
Figure 3 Comparison of disease activity-related outcomes after the index date between cases and controls. Comparison of disease
activity-related outcomes after the index date, between rheumatoid arthritis (RA) patients with incidental metabolic syndrome (Mets; cases) and
their matched controls (RA patients who did not develop incidental MetS up to last follow-up). (A) Median (range) cumulative disease activity
score evaluated in 28 joints after the index date in RA patients who developed incidental MetS and their controls. (B) Distribution (n (%)) of
patients and controls who achieved or maintained remission and of patients and controls with disease flare or who never achieved remission,
from the index date up to last follow-up.
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lence. A recent meta-analysis by Zhang and colleagues has
proven further evidence in support of a higher prevalence
of MetS in RA patients, with an overall odds ratio of 1.24
(95% confidence interval, 1.03 to 1.50), although geo-
graphic area and the criteria used influenced the associ-
ation [14]; interestingly, none of the 12 studies included in
the meta-analysis was performed in Mexican patients.
Conflicting results regarding this topic were highlighted in
two excellent reviews by da Cunha and colleagues in 2011
[35] and Ferraz-Amaro and colleagues in 2013 [36]; both
studies concluded that MetS is not uncommon in patients
with RA but mentioned published exceptions with regard
to a greater prevalence in RA patients [18,37-40]. More re-
cently, Mok and colleagues estimated a prevalence of 20%
in 699 Chinese patients, of whom 209 had disease dur-
ation of less than 2 years [41]. In most of the studies re-
ported (including exceptions), matching of controls has
been restricted to age and sex, and sometimes to race. We
performed a more precise matching, including characteris-
tics that do affect the prevalence of MetS in Mexican Mes-
tizo patients such as years of education [20], in addition to
age, gender, smoking habit, menopause status and urban
residency. This unique characteristic to our study, along
with a population with short disease duration and younger
age at diagnosis (mean age 38.1 years), may explain our
prevalence figure of MetS in RA patients in the lower
range (up to 18%), which in fact is similar to that reported
by Zonana-Nacach and colleagues in the only study per-
formed in Mexican patients [42]. Also, our prevalence fig-
ure of MetS in matched controls, which may beconsidered high, is similar to that reported in the National
Health and Nutrition Survey in 2006 [20], when analyzed
by age group.
We found among the individual components of MetS
that differences between patients and controls were ob-
served for the BMI component, which was more fre-
quent in controls; meanwhile, opposite tendencies were
seen for the hypertension and GLU components, par-
tially consistent with studies performed in early RA
[15,16]. More than one-half of our active RA patients
with MetS presented the GLU component; this figure
may be explained by a negative correlation of high-grade
inflammation with circulating adiponectin concentra-
tions as proposed by González-Gay and colleagues; their
study involved patients with severe RA in whom (low)
adiponectin concentrations further correlated with high
plasma GLU [43]. Ultimately, discrepancies with other
studies may be explained by the particular distribution
of individual components of the MetS in our population
along with distinctive epidemiological, clinical and sero-
logical characteristics of Mexican patients with RA.
Our early arthritis cohort of Mexican Mestizo patients
has particular characteristics [24,28,29] that were consid-
ered for the second aim of the study and confer rele-
vance to findings, such as a homogeneous population of
patients with early disease and substantial comorbidity
(real-life patients), standardized and complete follow-up
by the same rheumatologist in a real clinical setting,
periodic evaluation of comorbidity, treatment and
physician-reported and patient-reported outcomes, use
of conventional DMARDs according to a treat-to-target
Table 6 Comparison of characteristics between RA
patients who never achieved remission and those who
achieved and maintained remission (case–control study,
nested within the cohort)









(n = 46) (n = 14)
Socio-demographic
Female gender 40 (87%) 14 (100) 0.32
Age (years) 38.2 ± 10.5 38.7 ± 12.5 0.88
Years of formal
education
10.5 ± 8.8 10 ± 7.7 0.43




2 (5) 1 (7) 1





5.8 (4.1 to 7.7) 3.3 (1.6 to 6) 0.03
Patients with ACCP 38 (82.6) 13 (92.9) 0.67
Baseline DAS28 6 (4.6 to 6.8) 7.3 (6.5 to 7.8) 0.002
Baseline ESR (mm/hour) 24.5 (14.3 to 37) 43 (28.3 to 59.5) 0.012
Baseline CRP (mg/dl) 1 (0.3 to 3.4) 2.4 (1.4 to 6.1) 0.05
Baseline HAQ 1.4 (0.6 to 2) 2.3 (1.6 to 3) 0.008
Patients with erosions
at baseline
5 (11) 0 (0) 0.33
Follow-up (months) 88 (58.5 to 108) 87 (57 to 108) 0.96
Incidental MetS 19 (41.3) 11 (78.6) 0.03
Comorbid conditions
Patients with diabetes 1 (2.2) 0 (0) 1
Patients with
hypertension
1 (2.2) 0 (0) 1
Patients with
BMI ≥30 kg/m2





2 (2 to 2.5) 2.5 (2 to 2.75) 0.08
Patients with
corticosteroids
30 (65.2) 9 (64.3) 1
Data presented as n (%), mean ± standard deviation or median (range). ACCP,
antibodies to cyclic citrullinated peptides; BMI, body mass index; CRP, C-
reactive protein; DAS28, disease activity score evaluated in 28 joints; DMARD,
disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate;
HAQ, Health Assessment Questionnaire; MetS, metabolic syndrome; RA,
rheumatoid arthritis. aIn those who never achieved remission, complete
follow-up was considered.




Model 2 Model 3
DAS28 at baseline 0.44, 023 to 0.85 0.50, 0.21 to 0.85 0.42, 0.21 to 0.85
Incidental MetS 0.23, 0.05 to 1.00 0.18, 0.04 to 0.89 0.23, 0.05 to 1.09
Disease duration
at baseline
1.28, 0.94 to 1.74 1.26, 0.93 to 1.70
ACCP 0.20, 0.02 to 2.29
Age 0.97, 0.90 to 1.04
Data presented as Exp (β), 95% confidence interval. ACCP, antibodies to cyclic
citrullinated peptides; DAS28, disease activity score evaluated in 28 joints;
MetS, metabolic syndrome.
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this is the only study in which incident MetS is deter-
mined so cause–effect inferences on the relationship be-
tween MetS and disease activity were possible. We firstdescribed the MetS incidence rate as 8 per 100 persons/
year and showed that the annual MetS incidence rate
decreased after the third year; this can be explained by a
greater burden of disease activity at RA diagnosis and/or
by a more intensive search of comorbid conditions in
patients first attending a clinic. To our knowledge there
is no information available in the literature that may
help us to contrast these data.
We could not find a relation between prevalent MetS
and the different outcomes related to remission (as time
to remission and time on sustained remission). Similar
to results described in some studies, prevalent MetS was
not associated with disease activity parameters [37,38]
but with erosive disease, although the latter is generally
linked to a greater disease activity burden. Nonetheless,
the most relevant findings were that incidental MetS
and baseline disease activity were predictors for achiev-
ing and maintaining a remission status. Also, looking at
the problem from the other side of the coin, cumulative
disease activity and BMI were both predictors of inci-
dental MetS. Although there are published studies that
have established an association between MetS and
disease-related outcomes [14,16-19,37,38,44-47], data
based on a prospective design that allows risk evalua-
tions are very limited. Gremese and Ferraccioli in their
review described unpublished data from 115 long-
standing RA patients with disease activity and starting
anti-TNF; RA patients carrying MetS had lower chance
to achieve a good response [48]. Our data support that
MetS has an inflammatory milieu favoring the occur-
rence of RA or leading to a more severe disease. On the
contrary, MetS contributes to a poorer response to ther-
apy in RA patients, probably due to the additive effect of
its low-grade inflammation to the great inflammatory
burden of RA. The most relevant point from these ob-
servations may be related to the complex relationship of
the different pathways, cytokines and adipocyte-derived
mediators driving inflammation in RA patients with
MetS; as an example, proinflammatory cytokines such as
Parra-Salcedo et al. Arthritis Research & Therapy  (2015) 17:34 Page 10 of 11tumor necrosis factor alpha are involved in the patho-
genesis of insulin resistance while resistin (an adipocyte-
derived mediator) also plays an important role in the
inflammatory cascade and undergoes a dramatic reduc-
tion after anti-tumor necrosis factor alpha therapy [49].
In fact, the benefits of tumor necrosis factor alpha block-
ade in RA patients go far beyond the local (synovial) in-
flammatory process, and extend to other biological
actions such as improvement of endothelial dysfunction
and of insulin resistance [50].
Limitations of the study include the number of patients
studied, especially men. In addition, up to 50% of the pa-
tients had received corticosteroids, chloroquine and/or
methotrexate 1 month before entering the cohort, and
these drugs are known to affect the lipid profile and even-
tually alter the true prevalence of MetS [46,51]. Our clinic
is established in a tertiary care center, and there is a possi-
bility of patient selection bias; patients with mild RA may
especially be underrepresented. Also, our cohort of
patients with early disease is limited to a population of
Mexican Mestizos who have particular genetic background,
socio-demographic characteristics, treatment availability
and health system referral – all of these factors potentially
affect both the disease itself and MetS; accordingly, our re-
sults may not be generalized. Owing to the limited years of
follow-up of our cohort, the impact of MetS on CV out-
comes was not assessed, and neither was the impact of in-
dividual components of MetS, which have been shown to
perform better (than currently recommended MetS defini-
tions) in identifying subclinical atherosclerosis in RA pa-
tients [52]. A limited number of comorbid conditions
were assessed in our study (obesity, hypertension and
diabetes) while others such as hyperuricemia and
hypothyroidism that are recognized to be independent
CV risk factors in the general population and in RA pa-
tients were not [53]. Finally, during 10-year follow-up
there were up to 20% missing data and an imputation
methodology was used.
Conclusions
Mexican Mestizo RA patients referred to a tertiary care
center had a prevalence of MetS variable upon the cri-
teria applied, from 11 to 18%, but lower than matched,
apparently healthy controls. Up to 9 years of follow-up,
the MetS incidence rate was 34.5% and the annual MetS
incidence rate decreased after the third year. Disease ac-
tivity and MetS had a complex association favoring a vi-
cious circle: greater cumulative disease activity and BMI
were both predictors of incidental MetS, while incidental
Mets and higher disease activity at baseline predicted
worse outcomes. In such a clinical context, it appears
that both MetS and disease activity need to be treated
and effectively controlled in order to impact disease out-
comes. Ultimately, CV risk will be also impacted.Abbreviations
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